Preferred Label : Crizanlizumab;
NCIt synonyms : Crizanlizumab-tmca;
NCIt definition : A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective
and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin
and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG)
on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell
adhesion molecule (CAM), translocates to the surface of activated endothelial cells
and platelets, upon stimulation, where it binds to its ligand and mediates the rolling
of platelets and neutrophils on activated endothelial cells. Therefore, blockade of
p-selectin may inhibit platelet aggregation, maintain blood flow and minimize sickle
cell-related pain crises (SCPC).;
UNII : L7451S9126;
CAS number : 1690318-25-2;
Drug name : Adakveo;
Molecule name : SelG1; SEG 101; SEG-101;
NCI Metathesaurus CUI : CL519758;
Codes from synonyms : 118;
Origin ID : C133543;
UMLS CUI : C4524703;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
- has_target
https://www.ema.europa.eu/en/medicines/human/EPAR/adakveo
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Crizanlizumab
Crizanlizumab
drug approval
europe
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
crizanlizumab
orphan drug production
pain
young adult
adult
anemia, sickle cell
drug therapy, combination
hydroxyurea
infusions, intravenous
P-Selectin
product surveillance, postmarketing
Vaso-Occlusive Crisis
aged
pregnancy
breast feeding
drug evaluation, preclinical
crizanlizumab
crizanlizumab
antibodies, monoclonal
antibodies, monoclonal
---
